Related references
Note: Only part of the references are listed.Isocitrate dehydrogenase mutations in myeloid malignancies
B. C. Medeiros et al.
LEUKEMIA (2017)
Pretreatment D-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia
J. Balss et al.
LEUKEMIA (2016)
Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120
K. C. Birendra et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate
A. Chaturvedi et al.
LEUKEMIA (2016)
Getting a handle on hereditary CEBPA mutations
Courtney D. DiNardo
BLOOD (2015)
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia
Ujunwa C. Okoye-Okafor et al.
NATURE CHEMICAL BIOLOGY (2015)
Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1
Mindy I. Davis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
Anuhar Chaturvedi et al.
BLOOD (2013)
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2013)
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China
Jiang-Han Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Julie-Aurore Losman et al.
SCIENCE (2013)
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Dan Rohle et al.
SCIENCE (2013)
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang et al.
SCIENCE (2013)
Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase
Baisong Zheng et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
Rob A. Cairns et al.
BLOOD (2012)
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
Masato Sasaki et al.
NATURE (2012)
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo
Janeta Popovici-Muller et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation
Tatsuhiro Shibata et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
M. Fernanda Amary et al.
JOURNAL OF PATHOLOGY (2011)
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer
Avaniyapuram Kannan Murugan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
Felicitas Thol et al.
BLOOD (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations
Leopold Sellner et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis
Felicitas Thol et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor
Katharina Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
Stefan Gross et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (vol 462, pg 739, 2010)
Lenny Dang et al.
NATURE (2010)
Somatic Mutations of IDH1 and IDH2 in the Leukemic Transformation of Myeloproliferative Neoplasms
Anthony Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Share Paper
